Results 61 to 70 of about 22,030 (174)

Mumps Postexposure Prophylaxis with a Third Dose of Measles-Mumps-Rubella Vaccine, Orange County, New York, USA

Emerging Infectious Diseases, 2013
Although the measles-mumps-rubella (MMR) vaccine is not recommended for mumps postexposure prophylaxis (PEP), data on its effectiveness are limited. During the 2009–2010 mumps outbreak in the northeastern United States, we assessed effectiveness of PEP ...
Amy Parker Fiebelkorn, Jacqueline Lawler, Aaron T. Curns, Christina Brandeburg, Gregory S. Wallace   +4 more
doaj   +1 more source

Resurgence of Mumps in India: A Call to Reintroduce MMR into the Immunization Program

National Journal of Community Medicine
The recent rise in mumps outbreaks across several Indian states exposes a critical gap in the national immunization framework specifically, the absence of mumps vaccination in the Universal Immunization Programme (UIP).
Lalithambigai Chellamuthu, Anlin Jenisha
doaj   +1 more source

Mumps resurgence despite MMR: Limitations of current vaccines and the need for new strategies

Human Vaccines & Immunotherapeutics
Mumps has reemerged globally despite widespread use of the measles – mumps – rubella (MMR) vaccine, contrasting with the successful control of measles and rubella.
Vipin M. Vashishtha, Unmesh Upadhyay
doaj   +1 more source

Serological evaluation of 52 children immunized with the combined measles, mumps and rubella vaccine

The Turkish Journal of Pediatrics, 1991
Fifty-two of 298 children vaccinated with the measles-mumps-rubella (MMR) vaccine at around the age of 16 months were evaluated for antibody titres against measles, mumps, and rubella.
B Topal, G Kanra, M Ceyhan
doaj  

The efficacy of 20% salicylic acid solution versus intralesional MMR vaccine combination with 20% salicylic acid solution in treatment of plane wart

Advanced Medical Journal
Background and objectives: Plane wart treatment is challenging; modalities such as cauterization and cryotherapy having a great probability to recur, as well as the risk of scarring, discomfort, and expensive costs.
Banu Muhammed Jaza Noori, Ali Mozan Dhahir Elethawi   +1 more
doaj   +1 more source

Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial

Human Vaccines & Immunotherapeutics, 2017
This phase III clinical trial was conducted to evaluate the immunogenicity and safety of the single-dose and multi-dose formulations of a novel MMR vaccine (live, freeze-dried) developed by M/s Cadila Healthcare Limited, India (Cadila MMR vaccine ...
Ashwani Sood, Monjori Mitra, Himanshu Arvind Joshi, Uma Siddhartha Nayak, Prashanth Siddaiah, T. Ramesh Babu, Samarendra Mahapatro, Jayesh Sanmukhani, Gaurav Gupta, Ravindra Mittal, Reinhard Glueck   +10 more
doaj   +1 more source

Safety analysis of a live attenuated mumps vaccine in healthy adolescents in China: A phase 4, observational, open-label trial. [PDF]

PLoS One, 2023
Hu W, Jia N, Meng W, Zhou T, Wang R, Xiong Y, Luan C, Zhang S.   +7 more
europepmc   +1 more source

Development of Improved Mumps Vaccine Candidates by Mutating Viral mRNA Cap Methyltransferase Sites in the Large Polymerase Protein. [PDF]

Virol Sin, 2021
Hao X, Wang Y, Zhu M, Zhou D, Liu R, Wang B, Huang YW, Zhao Z.   +7 more
europepmc   +1 more source

Genetic associations with mumps and rubella antibody response after MMR vaccination in 6- and 15-month-old children

Vaccine: X
Background: Measles, mumps, and rubella (MMR) vaccines have significantly improved public health worldwide. However, variation in vaccine response among immunized individuals poses a threat to both individual protection and herd immunity.
Jesper Kiehn Sørensen, Dorthe Maria Vittrup, Andreas Jensen, Michelle Malon, Anne Cathrine Zimakoff, Sejun Kim, Jonas Bybjerg-Grauholm, Simranjeet Kaur, Flemming Pociot, Lone Graff Stensballe, Jannet Svensson   +10 more
doaj   +1 more source

Mumps outbreak in an unimmunized population - Luanshya District, Copperbelt Province, Zambia, 2015

The Pan African Medical Journal, 2018
INTRODUCTION: Mumps is a vaccine-preventable viral disease that may cause deafness, orchitis, encephalitis or death. However, mumps vaccine is not included in Zambia's Expanded Program for Immunization.
Ernest Kateule, Ramya Kumar, Modest Mulenga, Victor Daka, Kelvin Banda, Raydel Anderson, Rebecca McNall, Marcia McGrew, Henry C Baggett, Webster Kasongo   +9 more
doaj   +1 more source